Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

Summary

This is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.

Timeline

Start

2022-03-21

Primary completion

2023-07-31

Completion

2023-07-31

Outcome

Outcome not reported

Stopped (Business): “An administrative decision was made to terminate the AT-1501-N205 study. This voluntary business-related decision was not related to the safety of tegoprubart (AT-1501). Available safety data demonstrated tegoprubart to be safe and well tolerated.”

Drugs

Indications